지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2013.1
- 수록면
- 79 - 85 (7page)
이용수
초록· 키워드
오류제보하기
Since the first description of non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation as a distinct clinical entity, studies have proved EGFR tyrosine kinase inhibitors (TKIs) as a first choice of treatment. The median response duration of TKIs as a first-line treatment for EGFR mutant tumors ranges from 11 to 14 months. However, acquired resistance to EGFR-TKIs is inevitable due to various mechanisms, such as T790M, c-Met amplification, activation of alternative pathways (IGF-1, HGF, PI3CA, AXL), transformation to mesenchymal cell or small cell features, and tumor heterogeneity. Until development of a successful treatment strategy to overcome such acquired resistance, few options are currently available. Here we provide a summary of the therapeutic options after failure of first line EGFR-TKI treatment for NSCLC.
목차
등록된 정보가 없습니다.
참고문헌 (42)
참고문헌 신청
Baselga J / 2002 / Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types / J Clin Oncol 20:4292~4302
Shepherd FA / 2005 / Erlotinib in previously treated non-small-cell lung cancer / N Engl J Med 353:123~132
Thatcher N / 2005 / Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) / Lancet 366:1527~1537
Cho BC / 2007 / Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib / J Clin Oncol 25:2528~2533
Lee DH / 2008 / Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment / Ann Oncol 19:2039~2042
Shepherd FA / 2005 / Erlotinib in previously treated non-small-cell lung cancer / N Engl J Med 353:123~132
Thatcher N / 2005 / Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) / Lancet 366:1527~1537
Cho BC / 2007 / Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib / J Clin Oncol 25:2528~2533
Lee DH / 2008 / Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment / Ann Oncol 19:2039~2042
이 논문의 저자 정보
최근 본 자료
댓글(0)
0